The subject invention provides a stable pharmaceutical composition comprising a therapeutically effective amount of laquinimod, an amount of a filler, and an amount of a lubricant, wherein the stable pharmaceutical composition is free of an alkalizing agent or an oxidation reducing agent. The subject invention also provides processes for making the stable pharmaceutical composition and sealed packages comprising the stable pharmaceutical composition. The subject invention additionally provides method for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis comprising administering to the subject a stable pharmaceutical composition as described herein. The subject invention further provides for use of a stable pharmaceutical composition as described herein for treating a subject afflicted with a form of multiple sclerosis or for alleviating a symptom of multiple sclerosis in a subject afflicted with a form of multiple sclerosis.本發明提供一種穩定醫藥組合物，其包含治療有效量之拉喹莫德、一定量之填充劑及一定量之潤滑劑，其中該穩定醫藥組合物不含鹼化劑或氧化還原劑。本發明亦提供製備該穩定醫藥組合物之方法及包含該穩定醫藥組合物之密封包裝。本發明另外提供治療罹患某一形式之多發性硬化之個體或減緩罹患某一形式之多發性硬化之個體之多發性硬化症狀的方法，該方法包含向該個體投與如本文所描述之穩定醫藥組合物。本發明進一步提供如本文所描述之穩定醫藥組合物之用途，其用於治療罹患某一形式之多發性硬化之個體或用於減緩罹患某一形式之多發性硬化之個體之多發性硬化症狀。
